Literature DB >> 8940211

Protection from Mycobacterium avium complex disease in human immunodeficiency virus-infected persons with a history of tuberculosis.

C R Horsburgh1, D L Hanson, J L Jones, S E Thompson.   

Abstract

Risk of Mycobacterium avium complex disease was examined in human immunodeficiency virus (HIV)-infected patients with and without a history of tuberculosis. Information was obtained by retrospective review of charts of patients in HIV clinics in 10 US cities. Among 1363 patients with <200 CD4 cells/mm3 seen at Grady Memorial Hospital (GMH), 11 (17%) of 66 with a history of a positive purified protein derivative (PPD) skin test acquired M. avium infection, while 29 (16%) of 185 who were PPD-negative (but not anergic) did not (P = .85). Only 4 (8%) of 49 GMH patients with a history of tuberculosis acquired M. avium infection compared with 252 (19%) of 1314 GMH patients without a history of tuberculosis (P = .05). Proportional hazards analysis of risk factors for M. avium infection among 441 persons with and 8702 persons without a history of tuberculosis in 9 other cities confirmed protection from M. avium infection in persons with a history of tuberculosis (relative risk, 0.52; 95% confidence interval, 0.36-0.76; P < .001). Prior tuberculosis provides protection against M. avium infection in HIV-infected persons, possibly by stimulation of antimycobacterial immunity.

Entities:  

Mesh:

Year:  1996        PMID: 8940211     DOI: 10.1093/infdis/174.6.1212

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

2.  Observed differences in virulence-associated phenotypes between a human clinical isolate and a veterinary isolate of Mycobacterium avium.

Authors:  K A Birkness; W E Swords; P H Huang; E H White; C S Dezzutti; R B Lal; F D Quinn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection.

Authors:  C F von Reyn; P L Williams; H M Lederman; J A McCutchan; S L Koletar; R L Murphy; S E Cohn; T Evans; A E Heald; D Colquhoun; E L Bassily; J S Currier
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Spectrum of clinical disease in a series of 135 hospitalised HIV-infected patients from north India.

Authors:  S K Sharma; Tamilarasu Kadhiravan; Amit Banga; Tarun Goyal; Indrish Bhatia; P K Saha
Journal:  BMC Infect Dis       Date:  2004-11-22       Impact factor: 3.090

5.  BCG Vaccination Induces M. avium and M. abscessus Cross-Protective Immunity.

Authors:  Getahun Abate; Fahreta Hamzabegovic; Christopher S Eickhoff; Daniel F Hoft
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

Review 6.  Virulence Mechanisms of Mycobacterium abscessus: Current Knowledge and Implications for Vaccine Design.

Authors:  Kia C Ferrell; Matt D Johansen; James A Triccas; Claudio Counoupas
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

Review 7.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.